|
The Framingham Study: Examining DNA Markers and Links to Diseases Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on The Framingham Study: Examining DNA Markers and Links to Diseases conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. The Framingham Study: Examining DNA Markers and Links to Diseases Clinical research trials and The Framingham Study: Examining DNA Markers and Links to Diseases medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like The Framingham Study: Examining DNA Markers and Links to Diseases. The Framingham Study: Examining DNA Markers and Links to Diseases Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a The Framingham Study: Examining DNA Markers and Links to Diseases clinical trial. Subjects typically recieve the finest healthcare available for their The Framingham Study: Examining DNA Markers and Links to Diseases condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Framingham Study: Examining DNA Markers and Links to Diseases  The Framingham Study: Examining DNA Markers and Links to Diseases
The Framingham Study: Examining DNA Markers and Links to Diseases
For Condition: Vascular Diseases
Status: Recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: Since 1948, residents of Framingham, Massachusetts, have participated in a program that collects blood samples and clinical data to provide a rare and valuable database for scientific research. The purpose of this study is to support this national resource by aiding in its research capacity. Specifically, researchers in this study will (1) investigate heart, lung, and blood diseases; stroke; memory loss; joint disease; bone loss; deafness; cancer; blood vessel diseases and other health conditions, and (2) examine DNA and its relationship to risk of developing these disease and health conditions. Approximately 330 families have participated in the Framingham Study. Participants will be required to undergo a four-hour exam and to take that exam every two years thereafter. During the exam, the Framingham investigators will (1) interview participants about medical status, health issues, and lifestyles; (2) perform a regular physical exam; (3) obtain blood and urine samples and administer a glucose-tolerance test; (4) supervise a brisk six-minute treadmill walk; (5) administer an ultrasound procedure; and (6) review and obtain copies of medical and hospital records. Participants will also be asked to complete a questionnaire at home regarding dietary and health habits.
Details: Many studies have shown that hematocrit (HCT) levels are associated with cerebrovascular disease, cardiovascular disease (CVD), peripheral vascular disease, as well as all-cause mortality. Twin studies have shown that HCT variation is largely determined by genetic factors with heritability estimated as 40% - 65%. So far, no linkage analysis in humans between HCT and DNA markers have been reported. The purpose of this protocol is to identify chromosome regions that contain quantitative trait loci (QTL) involved in controlling HCT levels. In the Framingham Study, a 10cM genome scan (about 400 markers) has been conducted in 330 families. HCT was measured in the original cohort and Framingham offspring. These data provide us the opportunity to undertake linkage analyses using variance component method to map quantitative trait loci (QTL) of HCT.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION /EXCLUSION CRITERIA The study population will include the members of the 330 Framingham Study families with genome scan.
Total Enrollment: 330
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 030219; 03-H-0219
Study Start Date: June 12, 2003
Record last reviewed: June 6, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00062777
Other Vascular Diseases Studies:
1. Trial of Aspirin and Vitamin E in Women (Women's Health Study - WHS)
2. Trial of Antihypertensive Intervention Management
3. Dietary Patterns, Sodium Intake and Blood Pressure (DASH - Sodium)
4. Antioxidants and Prevention of Early Atherosclerosis
5. Treatment of Hypertension
Related Studies:
Other Vascular Diseases Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
The Framingham Study: Examining DNA Markers and Links to Diseases
|
|
|
|
|
|
|
|
